Haemonetics Corporation 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on August 18, 2026, by Haemonetics Corporation (HAE), a Massachusetts-based medical technology company. The report discloses a material event occurring on August 14, 2026, involving a new commercial partnership.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity figures. It is a disclosure of a corporate event rather than a financial results report.
Material Changes and New Developments
- Supply Agreement: Haemonetics entered into a non-exclusive supply agreement with CSL Plasma Inc. (CSL).
- Scope: CSL may utilize Haemonetics' NexSys PCS devices with Persona PLUS technology and purchase related disposables in the United States.
- Commitments: The agreement contains no minimum purchase commitments.
- Implementation: Haemonetics anticipates CSL will transition a portion of its U.S. plasma collection centers to Haemonetics' equipment, but the specific scope and timing remain undetermined.
Guidance, Outlook, and Risks
- Guidance Update: The Company is not updating its previously issued fiscal 2027 guidance at this time due to the undetermined scope and timing of the agreement's implementation.
- Future Updates: Management expects to provide an update on the anticipated financial impact of this agreement during the second fiscal quarter earnings call in November 2026.
- Risks and Uncertainties: Forward-looking statements are subject to risks including customer demand, product adoption rates, the timing and volume of CSL purchases, and Haemonetics' manufacturing and supply capabilities.
Key Facts for Investor Verification
- Verify the exact terms of the non-exclusive agreement with CSL Plasma Inc. signed on August 14, 2026.
- Monitor the November 2026 earnings call for specific details on the scope of CSL's transition to Haemonetics devices.
- Confirm that no minimum purchase commitments exist in the current agreement.
- Review subsequent filings for any updates to fiscal 2027 guidance once implementation details are finalized.